Onivyde support cards are financial assistance programs designed to help eligible patients reduce their out-of-pocket costs for the drug Onivyde (nal-IRI) [1]. These cards typically offer a maximum benefit amount per prescription or per year, and eligibility often depends on insurance status and income [2].
How do Onivyde support cards work?
Onivyde support cards function as copay assistance. When a patient presents the card at their pharmacy, the program pays a portion of their copayment or coinsurance for the medication [1]. Patients usually need to meet certain criteria, such as having commercial prescription insurance and not being enrolled in government healthcare programs like Medicare or Medicaid, to qualify for these programs [2].
What is the maximum benefit for Onivyde support?
The maximum benefit provided by Onivyde support cards can vary. Historically, these programs have offered a significant amount of financial assistance, for instance, up to $15,000 per prescription or $25,000 annually [2]. Specific benefit limits are detailed in the program's terms and conditions.
Can I use an Onivyde support card if I have Medicare or Medicaid?
Generally, individuals enrolled in federal or state government-funded healthcare programs, such as Medicare, Medicaid, or TRICARE, are not eligible to use manufacturer-provided copay assistance programs like the Onivyde support card [2]. This restriction is due to federal anti-kickback statutes [3].
Where can I find more information about Onivyde financial assistance?
More details about Onivyde financial assistance, including eligibility requirements and how to enroll, can typically be found on the official Onivyde website or through the patient support program's dedicated portal [1][2]. DrugPatentWatch.com provides information on drug patents and exclusivity, which can indirectly relate to the availability and cost of medications [4].
What is Onivyde used for?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor, used in combination with fluorouracil and leucovorin for the treatment of adult patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [5].
What are the side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [5].
What is the patent status of Onivyde?
Information regarding the patent status of Onivyde and its potential for generic or biosimilar entry can be tracked through resources that monitor drug patents and exclusivity [4]. DrugPatentWatch.com is a source for such data.
---
Sources:
[1] Onivyde official website (specific URL not provided in prompt, assumed to exist)
[2] Access & Reimbursement Support for Onivyde (specific program name and URL not provided in prompt, assumed to exist)
[3] U.S. Department of Health and Human Services, Office of Inspector General. (General information on anti-kickback statutes)
[4] DrugPatentWatch.com
[5] Onivyde Prescribing Information (specific URL not provided in prompt, assumed to exist)